Ninety ALLEVIATE patients ( @ % BILAG A , mean BILAG score @ ) were randomized to receive @ mg/m ( @ ) ( n = @ ) or @ mg/m ( @ ) ( n = @ ) epratuzumab or placebo ( n = @ ) , plus standard of care , in @-week cycles .